Chronic migraine: Comorbidities, risk factors, and rehabilitation

Internal and Emergency Medicine

Volumn 5, Issue SUPPL. 1, 2010, Pages 13-19

  Negro, Andrea ^a   D'Alonzo, Lidia ^a   Martelletti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic migraine; Comorbidity; Detoxification; Medication overuse headache; Rehabilitation; Reprophylaxis

Indexed keywords

ANALGESIC AGENT; PRESCRIPTION DRUG; TRYPTAMINE DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; COMORBIDITY; DISEASE COURSE; DRUG DETOXIFICATION; HUMAN; ITALY; LIFESTYLE; MENTAL DISEASE; MIGRAINE; RISK FACTOR; WITHDRAWAL SYNDROME;

ANALGESICS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; DISEASE PROGRESSION; HUMANS; ITALY; LIFE STYLE; MENTAL DISORDERS; METABOLIC DETOXICATION, DRUG; MIGRAINE DISORDERS; PRESCRIPTION DRUGS; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; TRYPTAMINES;

EID: 77957120046     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0457-7     Document Type: Article

References (58)

1. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26: 742-746.
2. Stovner LJ, Andree C (2010) Prevalence of headache in Europe: a review of the Eurolight project. J Headache Pain. doi: 10. 1007/s10194-010-0217-0.
3. Silberstein S, Olesen J, Bousser MG et al (2005) The international classification of headache disorders, 2nd edn (ICHD-II). Revised of criteria for 8. 2 medication-overuse headache. Cephalalgia 25: 460-465.
4. Allena M, Katsarava Z, Nappi G, the COMOESTAS Consortium (2009) From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. J Headache Pain 10: 71-76.
5. Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication overuse headache. Lancet Neurol 9: 391-401.
6. Rossi P, Jensen R, Nappi G, Allena M, the COMOESTAS Consortium (2009) A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain 10: 407-417.
7. Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? Curr Opin Neurol 22: 269-276.
8. Pompili M, Serafini G, Di Cosimo D, Innamorati M, Lester D, Forte D, Girardi N, De Filippis S, Tatarelli R, Martelletti P (2010) Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat 6: 81-91.
9. Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P (2009) Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain 10: 283-290.
10. Etminan M, Takkouche B, Isorna FC, Samii A (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330: 63-65.
11. Kurth T (2007) Migraine and ischaemic vascular events. Cephalalgia 27: 967-975.
12. Tzourio C, Tehindrazanarivelo A, Iglesias S et al (1995) Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 310: 830-833.
13. Chang CL, Donaghy M, Poulter N (1999) Migraine and stroke in young women: case-control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Br Med J 318: 13-18.
14. Kurth T, Gaziano JM, Cook NR et al (2006) Migraine and risk of cardiovascular disease in women. JAMA 296: 283-291.
15. Stang PE, Carson AP, Rose KM et al (2005) Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 64: 1573-1577.
16. Kruit MC, van Buchem MA, Hofman PAM et al (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291: 427-434.
17. Spector JJ, Kahn SR, Jones SR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123: 612-634.
18. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 339: b3914.
19. Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, Lipton RB (2010) Migraine and cardiovascular disease. A population-based study. Neurology 74: 628-635.
20. Schwedt TJ (2009) The migraine association with cardiac anomalies, cardiovascular disease and stroke. Neurol Clin 27: 513-523.
21. Dalla Volta G, Guindani M, Zavarise P et al (2005) Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype. J Headache Pain 6: 328-330.
22. Ferrarini G, Malferrari G, Zucco R et al (2005) High prevalence of patent foramen ovale in migraine with aura. J Headache Pain 6: 71-76.
23. Tembl J, Lago A, Sevilla T et al (2007) Migraine, patent foramen ovale and migraine triggers. J Headache Pain 8: 7-12.
24. Jesurum JT, Fuller CJ, Velez CA et al (2007) Migraineurs with patent foramen ovale have larger right-to left shunt despite similar atrial septal characteristics. J Headache Pain 8: 209-216.
25. Wilmshurst PT, Nightingale S, Walsh KP et al (2005) Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke for haemodynamic reasons. Lancet 356: 1648-1651.
26. Azarbal B, Tobis J, Suh W et al (2005) Association of interatrial shunts and migraine headaches. J Am Coll Cardiol 45: 489-492.
27. Thenganatt J, Schneiderman J, Hyland RH et al (2006) Migraines linked to intrapulmonary right-to-left shunt. Headache 46: 439-443.
28. Litman GI, Friedman HM (1978) Migraine and the mitral valve prolapse syndrome. Am Heart J 96: 610-614.
29. Spence JD, Wong DG, Melendez LJ et al (1984) Increased prevalence of mitral valve prolapse in patients with migraine. Can Med Assoc J 131: 1457-1460.
30. Carerj S, Narbone MC, Zito C et al (2003) Prevalence of atrial septal aneurysm in patients with migraine: an echocardiographic study. Headache 43: 725-728.
31. Truong T, Slavin L, Kashani R et al (2008) Prevalence of migraine headaches in patients with congenital heart disease. Am J Cardiol 101: 396-400.
32. Innamorati M, Pompili M, De Filippis S, Gentili F, Erbuto D, Lester D, Tamburello A, Iacorossi G, Cuomo I, Dominici G, Tatarelli R, Martelletti P (2009) The validation of the Italian perceived disability scale (IPDS) in chronic daily headache sufferers. J Headache Pain 10: 21-26.
33. Oedegaard KJ, Angst J, Neckelmann D, Fasmer OB (2005) Migraine aura without headache compared to migraine with aura in patients with affective disorders. J Headache Pain 6: 378-386.
34. Franchini L, Bongiorno F, Dotoli D, Rainero I, Pinessi L, Smeraldi E (2004) Migraine headache and mood disorders: a descriptive study in an out-patient psychiatric population. J Affect Disord 81: 157-160.
35. Cuvellier JC, Carvalho S, Mars A, Auvin S (2009) Study on management of pediatric migraine by general practitioners in northern France. J Headache Pain 10: 167-175.
36. Cuvellier JC, Donnet A, Guégan-Massardier E, Nachit-Ouinekin F, Parain D, Vallée L (2009) Treatment of primary headache in children: a multicenter hospital-based study in France. J Headache Pain 10: 447-453.
37. Pompili M, Serafini G, Innamorati M, Serra G, Dominici G, Fortes-Lindau J, Pastina M, Telesforo L, Lester D, Girardi P, Tatarelli R, Martelletti P (2010) Patient outcome in migraine prophylaxis: the role of psycopharmacological agents. Patient Relat Outcome Meas 1: 1-12.
38. Villani V, Bruti G, Mostradini C, Di Stani F, Scattoni L, Dugoni D, Vanacore N, Cerbo R (2005) Migraine in the Emergency Department: a psychometric study of a migraine "repeaters" sample. J Headache Pain 6: 301-303.
39. De Filippis S, Erbuto D, Gentili F, Innamorati M, Lester D, Tatarelli R, Martelletti P, Pompili M (2008) Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache. J Headache Pain 9: 349-357.
40. Vargas BB, Dodick DW (2009) The face of chronic migraine: epidemiology, demographics and treatment strategies. Neurol Clin 27: 467-479.
41. Buse DC, Marcia FT, Rupnow FT, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84: 422-435.
42. Farinelli I, Dionisi I, Martelletti P (2010) Rehabilitating chronic migraine complicated by medication overuse headaches: how we can prevent relapse? Int Emerg Med. doi: 10. 1007/s11739-010-0410-9.
43. Trucco M, Meineri P, Ruiz L, on behalf of the "gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee" (Neurological Hospital Interregional Group for the Study of Headaches) (2010) Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain 6: 334-337.
44. Hagen K, Jensen R, Bøe MG, Stovner LJ (2010) Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain. doi: 10. 1007/s10194-010-0221-4.
45. Rossi P, Faroni JV, Nappi G (2010) Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. doi: 10. 1111/j. 1468-1331. 2010. 03157. x.
46. Lovell BV, Marmura MJ (2010) New therapeutic developments in chronic migraine. Curr Opin Neurol 23: 254-258.
47. Farinelli I, Coloprisco G, De Filippis S, Martelletti P (2006) Long-term benefits of botulinum toxin type A (Botox) in chronic daily headache: a five-year long experience. J Headache Pain 7: 407-412.
48. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, on behalf of PREEMPT 1 Trial. (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30: 793-803.
49. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, on behalf of the PREEMPT 2 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30: 804-814.
50. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener H-C, Brin MF, on behalf of the PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Pooled a results from the double-blind, randomized, placebo-controlled phases of the PREEMPT Clinical Program. Headache 50: 921-936.
51. Ruiz L, Ferrandi D (2009) Topiramate in migraine progression. J Headache Pain 10: 419-422.
52. Stovner LJ, Tronvik E, Hagen K (2009) New drugs for migraine. J Headache Pain 10: 395-406.
53. Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P (2009) Future drugs for migraine. Int Emerg Med 4: 367-373.
54. ®) for the prophylactic treatment of chronic migraine: a pilot study. Headache 49: 1466-1478.
55. Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P (2010) Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 11: 151-156.
56. Di Lorenzo C, Di Lorenzo G, Sances G et al (2009) Drug consumption in medication overuse headache is influenced by brain derived neurotrophic factor Val66Met polymorphism. J Headache Pain 10: 349-355.
57. Simmaco M, Borro M, Missori S, Martelletti P (2009) Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Expert Rev Neurother 9: 1267-1269.
58. Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P (2010) Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain. doi: 10. 1007/s10194-010-0241-0.